|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.322 SEK | -0.75% |
|
-4.20% | -23.80% |
| May. 08 | Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 14 | Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near future to strengthen its financial position.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source
| 1st Jan change | Capi. | |
|---|---|---|
| -23.80% | 8.82M | |
| +20.82% | 127B | |
| +21.96% | 116B | |
| +23.52% | 27.69B | |
| -22.97% | 19.62B | |
| -17.08% | 16.26B | |
| -19.03% | 15.49B | |
| +11.66% | 14.81B | |
| -48.41% | 14.39B | |
| +54.78% | 14.11B |
SPRINT BIOSCIENCE AB 
